UPDATE: Mizuho Securities USA Initiates Coverage on Epizyme with Buy Rating, $35 PT on Epigenetics Pure Play

In a report published Friday, Mizuho Securities USA analyst Peter Lawson initiated coverage on

with a Buy rating and $35.00 price target. In the report, Mizuho Securities USA noted, “We are initiating coverage of shares of Epizyme with a Buy rating and a price target of $35. Epizyme is a pure-play on epigenetics, a gene regulatory system that can be exploited to target cancer cells. While the company's pipeline is early phase, valuation is supported by a series of significant biopharmaceutical partners, a series of 4Q14 Phase I readouts, and a platform and IP for further discovery.” Epizyme closed on Thursday at $28.20.